Reversible inhibition of sperm under guidance
Revision as of 02:20, 18 January 2024 by Robert Brockway (talk | contribs) (Robert Brockway moved page RISUG to Reversible inhibition of sperm under guidance)
Reversible inhibition of sperm under guidance (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is the development name of a male contraceptive injection developed at IIT Kharagpur in India by the team of Dr. Sujoy K. Guha.[citation needed]
RISUG has been patented in India, China, Bangladesh, and the United States.[1] Phase III clinical trials were underway in India, and were slowed by insufficient volunteers.[1]
Beginning in 2011, a contraceptive product based on RISUG, Vasalgel, was under development in the US by Parsemus Foundation.[2] In 2023, the patent for Vasalgel was acquired by NEXT Life Sciences, Inc., which plans to bring the technology to market under the name Plan A for Men.[3]